Physician profile
Ivan Antonevich
NPI 1043256118
$12,750.77
in general payments reported to CMS, 2019-2025
37 companies · $1,727 in 2025
The $1,727 reported for 2025 was more than what 75% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,434 · 2020: $549 · 2021: $800 · 2022: $3,434 · 2023: $1,679 · 2024: $2,128 · 2025: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,533.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,470.20 | 2019-2025 | Proclaim, Eterna, Ionicrf |
| Boston Scientific Corporation | $2,229.23 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, General - Therapies |
| Medtronic USA, INC. | $2,039.54 | 2019-2020 | |
| Abbvie INC. | $2,030.28 | 2022-2025 | Botox |
| Allergan, INC. | $325.20 | 2019-2022 | |
| Si-Bone, INC. | $324.55 | 2022 | |
| Medtronic, INC. | $246.81 | 2021-2025 | Intellis Adaptivestim |
| Pfizer INC. | $240.15 | 2019-2024 | |
| Nevro Corp. | $165.24 | 2019-2024 | Senza |
| Ipsen Biopharmaceuticals, INC | $155.08 | 2021-2024 | Dysport |
| Globus Medical, INC. | $143.14 | 2025 | Senza |
| Avanos Medical | $118.62 | 2024-2025 | Standard Rf Disposables |
| Glaxosmithkline, LLC. | $116.20 | 2019-2021 | |
| Lundbeck LLC | $105.90 | 2022-2025 | Vyepti |
| Merz Pharmaceuticals, LLC | $100.77 | 2021-2025 | Xeomin |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Antonevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.